Vienna, Austria – May 9th 2025 – Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its ...

Clients purchasing Biomay´s Cas9 will ... cell therapies. The CRISPR/Cas system, a transformative gene-editing technology, whose discovery was honored with the 2020 Nobel Prize in Chemistry ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) are two incredibly innovative biotechs, but ...

Iovance Biotherapeutics' lead medicine is generating growing sales and seeking plenty of label expansions. CRISPR Therapeutics has exciting gene-editing candidates in the works. However, these ...

A U.S. company develops a trait that it says provides genetic resistance to sclerotinia, which can be challenging for growers ...

CRISPR is leveraging the Nobel Prize-winning CRISPR/Cas9 technology to develop transformative therapies. CRISPR aims to cure genetic diseases by precisely editing DNA, positioning it as a ...

In 2020, the Nobel Prize in Chemistry was awarded to ... “Most of them [NGTs] now, they are made through the CRISPR-Cas9 system,” said Brambilla. Cas-9 is an enzyme, a type of protein ...

Casgevy (exagamglogene autotemcel or exa-cel) became the first drug based on the CRISPR/Cas9 gene-editing technology ... which earned its discoverers a Nobel Prize in 2020. The one-shot therapy ...

In October, CRISPR Therapeutics co-founder Emmanuelle Charpentier and Intellia co-founder Jennifer Doudna shared the 2020 Nobel Prize in Chemistry for their work on CRISP/Cas9. Companion ...